Sanofi's experimental eczema drug amlitelimab falls short of expectations, raising concerns about the company's ability to replace Dupixent's revenue after patent expiry.
St. Louis Fed's Musalem backs current monetary policy ahead of September meeting, citing full employment and inflation slightly above target.
Fed Governor Waller advocates multiple interest rate cuts starting in September, signaling a potential shift in the Fed's monetary policy.
Sanofi's experimental eczema drug amlitelimab falls short of expectations, raising concerns about the company's ability to replace Dupixent's revenue after patent expiry.
St. Louis Fed's Musalem backs current monetary policy ahead of September meeting, citing full employment and inflation slightly above target.
Fed Governor Waller advocates multiple interest rate cuts starting in September, signaling a potential shift in the Fed's monetary policy.
